A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Top Cited Papers
Open Access
- 18 March 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e81-e89
Abstract
Background: Integrase inhibitors (INSTI) and tenofovir alafenamide (TAF) have been associated with greater weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF), but the effects of an antiretroviral regimen switch on weight are unclear. Methods: This 48-week, 3 parallel group, open-label, multicenter, randomized controlled trial (NCT04636437) in people with HIV and obesity on an INSTI (bictegravir, dolutegravir, or raltegravir) with TAF/emtricitabine (FTC) assessed whether switching to the NNRTI doravirine (DOR) with TAF/FTC or TDF/FTC results in weight loss or stabilization. Treatment effects were estimated using linear regression adjusted for sex, race, and entry weight. Results: Of 147 participants randomized, 145 initiated their assigned treatment. At entry, median age was 49 years; BMI was 34.9 kg/m2, and time on INSTI+TAF/FTC was 3.4 years; 49% were female and 53% Black. After 48 weeks, estimated mean change in weight was -0.47% (95% confidence interval [CI]: -2.09,1.14) for the DOR+TAF/FTC arm, -2.73% (-4.22, -1.23) for DOR+TDF/FTC, and -1.84% (-3.37, -0.30) for INSTI+TAF/FTC. Estimated mean difference in weight change at 48 weeks for DOR vs. INSTI (both with TAF/FTC) was 1.36 percentage points (97.5% CI: -1.20,3.92), and -0.89 percentage points (-3.34,1.57) for DOR+TDF/FTC vs. INSTI+TAF/FTC. There was no evidence of variation by sex or race, nor of treatment differences for changes in fasting lipids, insulin resistance, fat mass, or bone mineral density. Conclusions: In people with HIV and obesity, switching from an INSTI+TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (UM1AI068634)
- National Institutes of Health (UM1AI068636)
- National Institutes of Health (UM1AI106701)
- National Institutes of Health (UM1AI69452)
- National Institutes of Health (UM1AI69412)
- National Institutes of Health (UM1AI69501)
- National Institutes of Health (UM1AI69423)
- National Institutes of Health (UM1AI69470)
- National Institutes of Health (UM1AI69432)
- National Institutes of Health (UM1AI69465)
- National Institutes of Health (UM1AI69419)
- National Institutes of Health (UM1AI69471)
- National Institutes of Health (UM1AI69494)
- National Institutes of Health (UM1AI69534)
- National Institutes of Health (UM1AI69418)
- National Institutes of Health (UM1AI69424)
- National Institutes of Health (UM1AI69496)
- National Institutes of Health (UM1AI69511)
- National Institutes of Health (UM1AI69481)
- National Institutes of Health (UM1AI69439)
- National Institutes of Health (UM1AI154466)
- National Institutes of Health (P30AI110527)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020593)
- Merck
This publication has 22 references indexed in Scilit:
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialThe Lancet HIV, 2025
- DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight GainClinical Infectious Diseases, 2024
- Antiretrovirals and Weight Change: Weighing the EvidenceClinical Infectious Diseases, 2024
- Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTGClinical Infectious Diseases, 2022
- Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialClinical Infectious Diseases, 2022
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and CanadaJournal of the International AIDS Society, 2020
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with ObesityCell Metabolism, 2016
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and CanadaAIDS Research and Human Retroviruses, 2016
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013